A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: A double-blind, randomized, placebo-controlled trial

Trends in Medicine

Volumn 6, Issue 3, 2006, Pages 191-199

  Cazzola, Mario ^a,b  

^a CARDARELLI HOSPITAL   (Italy)

^b NONE   (Italy)

Author keywords

Acute exacerbation; Bacterial lysate; Bronchitis; Cor pulmonale; Prevention

Indexed keywords

ANTIBIOTIC AGENT; BACTERIUM LYSATE; ISMIGEN; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COR PULMONALE; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 33746926753     PISSN: 15942848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2005. Available at: http://www.goldcopd.com. Accessed March 13, 2006.
3. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000; 117 (suppl 2): 380S-385S.
4. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204.
5. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161:1608-1613.
6. Gibson PG, Wiodarczyk JH, Wilson AJ, et al. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J Quai Clin Pract 1998; 18:125-133.
7. Wilson R. The role of infection in COPD. Chest 1998; 113:2425-2485.
8. Anderson HR, Spix C, Medina S, et al. Air pollution and daily admissions of chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project. Eur Respir J 1997; 10:1064-1071.
9. Martinez FJ. Acute exacerbations of chronic bronchitis diagnosis and therapy. J Clin Outcomes Manage 2004; 11:659-673.
10. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57:847-852.
11. Staykova T, Black P, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis. The Cochrane Library, Issue 4, John Wiley & Sons, Ltd, Chichester, United Kingdom (2004).
12. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99 (Suppl 6B):3S-7S.
13. Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination, Chest 2004; 125:2011-2020.
14. Cazzola M, Salzillo A, De Giglio C, et al. Treatment of acute exacerbation of severe-to-very severe COPD with azithromycin in patients vaccinated against Streptococcus pneumoniae. Respir Med 2005; 99:663-669.
15. Orcel B, Delclaux B, Baud M, et al. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J 1994; 7:446-452.
16. Collet JP, Shapiro S, Ernst P, et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156:1719-1724.
17. Steurer-Stey C, Bachmann LM, Steurer J, et al. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. Chest 2004; 126:1645-1655.
18. Cassone A. Vaccini e vaccinazioni antinfettive. Istituto Superiore della Sanita. Accademia Nazionale di Medicina, 2002.
19. Macchi A, Della Vecchia L. Open comparative, randomized controlled clinical study of a new immunostimulating bacterial lysate in the prophylaxis of upper respiratory tract infections. Arzneim-Forsch/Drug Res 2005; 55:n 5.
20. Rossi S, Tazza R. Efficacy and safety of a new immunostimulating bacterial lysate in the prophylaxis of acute lower respiratory tract infection. Arzneim-Forsch/Drug Res 2004; 54:n 50.
21. Marchant A, Duchow J, Goldman M. Adhesion molecules in antibacterial defenses: Effects of bacterial extracts. Respiration 1992; 59 (Suppl 3):24-27.
22. Marchant A, Goldman M. OM-85 BV upregulates the expression of adhesion molecules on phagocytes through a CD 14-independent pathway. Int J Immunopharmacol 1996; 18:259-262.
23. Duchow J, Marchant A, Delville JP, et al. Upregulation of adhesion molecules induced by Broncho-Vaxom on phagocytic cells. Int J Immunopharmacol 1992; 14:761-766.
24. Wybran J, Libin M, Schandene L. Activation of natural killer cells and cytokine production in humans by bacterial extracts (OM-85 BV). Lung 1990; 168 (Suppl):720-725.
25. Xinogalos S, Duratsos D, Varonos D. Clinical effectiveness of Broncho-Vaxom in patients with chronic obstructive pulmonary disease. Int J Immunother 1993; 9:135-142.
26. Tricarico D, Varricchio A, D'Ambrosio S, et al. Prevention of recurrent upper respiratory tract infections in a community of cloistered nuns using a new immunostimulating bacterial lysate. Arzneim-Forsch/Drug Res 2004; 54:n 57.
27. Cogo R, Ramponi A, Scivoletto G, et al. Prophylaxis for acute exacerbations of chronic bronchitis using an antibacterial sublingual vaccine obtained through mechanical lysis: a clinical and pharmacoeconomics study. Acta Bio Medica Ateneo Parmensc 2003; 74:81-87.
28. Rosaschino F, Cattaneo L. Strategies for optimizing compliance of paediatric patients for seasonal antibacterial vaccination with sublingually administered Polyvalent Mechanical Bacterial Lysates (PMBL). Acta Bio Medica Ateneo Parmense 2004; 75:171-178.
29. Bowman LM, Holt PG. Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract. Infect Immun 2001; 69:3719-3727.
30. Bergemann R, Brandt A, Zoellner U, et al. Preventive treatment of chronic bronchitis: a meta-analysis of clinical trials with a bacterial extract (OM-85BV) and a cost effectiveness analysis. Monaldi Arch Chest Dis 1994; 49:302-307.
31. Jindal SK. Immunostimulation: does it work in COPD? Chest 2004; 126:1406-1408.
32. Cangemi G, Moranti B, Ferlazzo G, et al. The maturation of dendritic cells mediated by a Pouvalent Mechanical Bacterial Lysate (PMBL) results in the prophylaxis of upper respiratory tract infections. Arzneim-Forsch/Drug Res 2004; 54n 57.
33. Rossi G, Peri C, Raynal ME, et al. Natural occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. Immunol Lett 2003; 86:85.
34. Mascart F, Locht C. Le mucose, fonti di immunità. Le Scienze Dossier 2002; 13:40-45.
35. Niederman MS. Antibiotic therapy of exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15:59-70.
36. Dagan R, Klugman KP, Craig WA, et al. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of anti-microbial therapy. J Antimicrob Chemother 2001; 47:129-140.
37. Mauel J. Stimulation of immuno-protective mechanisms by OM-85 BV. Respiration 1994; 61:8-15.
38. Quezada A, Maggi L, Perez MA, et al. Effect of bacterial antigen lysate on IgG and IgA levels in children with recurrent infections and hypogammaglobulinemia. J Investig Allergol Clin Immunol 1999; 9:178-182.